Neurodegenerative diseases are a group of disorders characterized by the progressive loss of structure or function of neurons, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Acetylcholinesterase (AChE) plays a crucial role in the pathogenesis of these disorders by influencing inflammatory responses, cell apoptosis, oxidative stress, and aggregation of pathological proteins. Initially, neostigmine and physostigmine were identified by Scottish doctors as drugs that transiently improved skeletal muscle in patients with myasthenia gravis (MG) and were called the “Mary Walke effect” [4] . Once the diagnosis of MG is established, treatment should be to control the symptoms promptly. Acetylcholinesterase inhibitors (AChEI), such as pyridostigmine bromide, are the most common symptomatic treatment drugs, and their clinical efficacy has been confirmed by electrophysiological measurements [5] . Good clinical practice has supported their widespread use in the treatment of MG [6] . These drugs improve the structure and functional defects of the neuromuscular junction (NMJ) in patients with MG by prolonging the release of acetylcholine into the synaptic cleft. However, the use of AChEI can lead to excessive accumulation of acetylcholine at the NMJ and synapses, resulting in symptoms of muscarinic and nicotinic toxicity. In a study by Remijn-Nelissen et al. [7] , all patients treated with pyridostigmine for MG reported side effects (55% in the control group). The most common side effects were gastrointestinal gas, urinary urgency, muscle spasms, blurred vision, and hyperhidrosis, with 26% of patients discontinuing treatment due to intolerance. The study found that the most common reason for stopping pyridostigmine was diarrhea, abdominal cramps, and muscle cramps. Currently, AChEIs are commonly used for the clinical diagnosis of MG. In addition to using AChEIs alone to improve symptoms in early generalized MG treatment, other cases require combined medication. However, the combined pill has many adverse reactions and is difficult to control. Due to the many adverse reactions of AChEIs and to fully embody the concept of individualized precision medicine and maximize patient benefits, seeking new treatment strategies or developing new AChEI drugs at appropriate times is necessary.

The thymus has been recognized as the primary site of auto-sensitization in patients with AChR-MG, with most of these patients exhibiting thymus abnormalities, including follicular hyperplasia and thymoma [8] . The reported thymic hyperplasia in about 70% of patients with early-onset MG represents the rationale behind thymectomy as a therapeutic strategy to modify the natural course of MG. The underlying concept is to remove the site of the autoimmune attack that is responsible for self-sensitization [9] . Wolfe et al. [10] conducted a multi-center, randomized trial comparing the efficacy of thymectomy plus prednisone versus prednisone alone in patients with MG. The results showed that patients who underwent thymectomy had a lower time-weighted average severe quantitative muscle weakness score over three years compared to patients who received prednisone alone (6.15 vs. 8.99, p < 0.001). The thymectomy group also had a lower average requirement for prednisone (44 mg vs. 60 mg, p < 0.001). There were fewer patients in the thymectomy group compared to the prednisone-alone group who required azathioprine immunosuppression (17% vs. 48%, p < 0.001) or were hospitalized due to acute exacerbations (9% vs. 37%, p < 0.001). The two groups had no significant difference in the number of patients with treatment-related complications (p = 0.73). Still, the thymectomy group had fewer treatment-related symptoms related to immunosuppression (p < 0.001) and lower symptom-related distress (p = 0.003). This confirms the beneficial effect of thymectomy in patients with hyperplastic thymus and supports using thymectomy as a therapeutic strategy to modify the natural course of MG, particularly in non-thymoma MG patients. However, the significance of thymectomy in the treatment of non-thymoma MG has remained controversial until recent times. Zhang et al. [11] proposed that thymectomy applies to almost all patients with thymoma and severe myasthenia gravis patients with acetylcholine receptor antibodies. This includes patients with severe myasthenia gravis, especially young female patients; patients who are refractory to or intolerant of medical therapy; patients with thymic tumors or thymic enlargement; and patients with thymic inflammation or other severe comorbidities. It is particularly suitable for patients with acetylcholine receptor antibodies, severe myasthenia gravis, symptoms not limited to ocular myasthenia gravis, age < 50 years, and short duration of severe myasthenia gravis. A study has shown [12] that among 46 patients with severe myasthenia gravis undergoing thymectomy, thymoma (23.96%) was more common in elderly patients (53 ± 20 years old compared to 33 ± 24 years old) and males (54.5% compared to 18.8%). One year after thymectomy, 28.2% of patients had a poor prognosis, while 54.3% of patients had a good prognosis. Thymectomy in patients with MG can have a wide range of histological findings, from normal thymus to thymoma, with a preference for cortical phenotype. Still, there may be some errors in pathological specimens [13] . The incidence and prevalence of MG patients with thymoma are relatively low, and the inconsistent results of various studies and the need for long-term observation of treatment efficacy make it challenging to generate compelling data. A comprehensive analysis suggests that thymectomy can be beneficial under certain conditions, as it can significantly reduce the medication dosage required by postoperative MG patients. For MG patients with thymoma, the risk of surgery should be jointly considered by thoracic surgeons and neurologists, often under stable conditions, to reduce the incidence of postoperative crisis. However, surgery may not significantly improve MG symptoms in patients with malignant thymoma, as it primarily aims to treat the thymoma itself.

Immunosuppression is a common clinical approach for treating MG, including “broad-spectrum” immunosuppressive therapy using drugs such as corticosteroids, azathioprine, mycophenolate mofetil, methotrexate, ciclosporin, tacrolimus, etc. In 1935, Simon [14] reported the effectiveness of using pituitary extracts to treat MG. This may be the first description of the therapeutic effect of corticosteroids on MG. However, there is currently no standard oral corticosteroid dosing regimen in guidelines. Glucocorticoids (GC) are the preferred treatment for MG, based on their rapid onset of action, low cost, and high efficiency, which can improve the condition of 80% - 95% of patients. Once the symptoms are relieved, the corticosteroid dose should be reduced or stopped to minimize long-term side effects [15] . With their widespread use, the side effects of corticosteroids have been extensively studied, including side effects ranging from mild to severe, affecting multiple bodily systems, including musculoskeletal (such as osteoporosis and muscle disease), metabolic and endocrine (such as hyperglycemia, Cushing’s syndrome, weight gain, and hirsutism), immunological (such as infection), cardiovascular (such as hypertension and arrhythmia), gastrointestinal (such as gastric ulcer and bleeding), neuropsychiatric (such as mood changes and psychosis), ocular (such as glaucoma and cataracts), and laboratory abnormalities (such as hypokalemia) [16] . Menon D [17] et al. believe that this type of treatment has many drawbacks, such as increasing the risk of life-threatening infections, widespread systemic side effects, delayed onset of action, and an apparent increase in the risk of malignancies and drug toxicity. In clinical practice, most patients experience significant side effects after long-term use of immunosuppressants. At the same time, reducing the dosage of immunosuppressants is associated with a risk of recurrence. If the reduction is too rapid, the risk of recurrence increases even more. Therefore, GC is generally used as a first-line rescue treatment for MG patients experiencing side effects when using AChEI.

Plasma exchange has been widely used in autoimmune neurological diseases and is the standard treatment for myasthenic crisis and Guillain-Barre syndrome (GBS) [28] . Currently, plasma exchange (PE) is commonly used for patients with acute exacerbation of MG. Safa et al. [29] suggested that patients receiving intravenous immunoglobulin (IVIG) or plasma exchange (PLEX) as first-line treatment have better outcomes in improving MG symptoms compared to patients receiving steroid treatment alone (95% vs 63%, p = 0.011). Nagayasu et al. [30] conducted a study that showed preoperative plasma exchange may help improve the prognosis of MG patients after thymectomy. In early observational reports [31] , IVIG was effective in nearly 70% - 75% of MG patients. Peng et al. [32] believed that PE combined with IVIG could effectively enhance the immune function of MG patients and promote the prognosis, ensuring treatment safety. Japanese researchers have shown that PE can be applied to various neurological diseases to recognize immune involvement [33] . The most common illnesses treated by PE are MG, followed by autoimmune encephalitis/encephalopathy, multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), chronic inflammatory demyelinating polyneuropathy (CIDP), and GBS. Current MG guidelines recommend intravenous immunoglobulin or PE during the myasthenic crisis. Still, intravenous immunoglobulin or PE is expensive and often unavailable in developing countries, and there is a risk of blood-borne infections during plasma exchange therapy.

A study by Nair SS [34] et al. found that FcRn blockers and B cell depletion agents have shown promising efficacy in MG treatment regimens. Such drugs are most valuable for refractory MG patients, and their use in early severe patients may alleviate symptoms. Neonatal Fc receptor (nFcR) antagonists are a new class of drugs first used in MG [35] . The neonatal Fc receptor (FcRn) functions as the intracellular protective receptor for IgG [36] . Antagonizing FcRn to prevent its binding with IgG can accelerate the latter’s catabolism, reducing IgG levels, including pathogenic autoantibodies, thereby achieving therapeutic effects [37] . The ability of these drugs to rapidly reduce circulating Igs provides a new therapeutic option for antibody-mediated diseases; if proven effective, nFcR could become an alternative to intravenous immunoglobulin or plasma exchange, overcoming the increasing demand for human plasma or the feasibility of single donation in patients with poor vascular access [38] . Keller et al. [39] are developing therapeutic strategies that utilize FcRn function to enhance endogenous IgG degradation or increase the serum half-life of therapeutic Abs, which could significantly improve the treatment management of MG.

Efgartigimod is an Fc fragment, while rozanolixizumab, batoclimab, nipocalimab, and olisoxib are monoclonal antibodies against FcRn. Efgartigimod has been FDA-approved for managing refractory generalized myasthenia gravis (gMG) and is currently undergoing phase III trials for nipocalimab and batoclimab [40] . Studies have shown that efgartigimod improves health-related quality of life in gMG patients, with significant and rapid improvement in HRQoL observed up to 2 weeks after the first infusion of TC 8 and TC 1 [41] . In critical clinical trials of gMG patients, efgartigimod α rapidly reduced disease symptoms and improved quality of life [42] . Rozanolixizumab is also being developed to mitigate pathogenic IgG in autoimmune and alloimmune diseases [43] . In various phase I, II, and III trials to date, phase I trials have assessed the drug’s safety, tolerability, pharmacokinetics, and pharmacodynamics on circulating IgG concentrations. Pharmacokinetics showed nonlinear increases with dose, and serum IgG concentrations (IV and SC rozanolixizumab) had sustained dose-dependent reductions [44] . Phase II trials have investigated clinical efficacy and safety in gMG patients, with data suggesting that rozanolixizumab may provide clinical benefits to gMG patients, usually with good tolerability [45] . Compared to FcRn-targeted therapies, the regulation of classic FcγR function or signaling has been less studied in MG, and further research is needed to understand their biology and potential pathogenic role in MG. FcγR modulation may benefit several Ab-mediated autoimmune diseases [39] . This year, efgartigimod has been officially launched in China and approved by the National Medical Products Administration to be used in combination with conventional therapeutic drugs for the treatment of adult generalized myasthenia gravis patients with acetylcholine receptor (AChR) antibody positivity. This marks a milestone in helping MG patients improve muscle strength and quality of life.

B-cells are a vital element in the immunopathogenesis of MG, and drugs that selectively target these cells may be therapeutically relevant. Therefore, therapeutic approaches that target critical molecules of B-cells (primarily CD19 and CD20) are expected to be effective in treating MG [46] . CD20 plays a crucial role in B-cell growth and differentiation into plasma cells. Rituximab, a chimeric monoclonal antibody against the B-cell surface antigen CD20, depletes CD20-positive B-cells for 6 - 12 months, primarily through cell apoptosis and receptor downregulation. Its immune effects include reducing antigen presentation, reducing cytokine production, T-cell and macrophage activation, and upregulating Treg cells [47] . Compared to rituximab, epratuzumab is a humanized IgGκa monoclonal antibody that targets the CD19 surface antigen on B-cells. A placebo-controlled trial for NMO spectrum disorders showed that the treatment group had a lower recurrence rate, indicating that epratuzumab may also be a targeted B-cell therapy option for MG [48] . In addition, inflammatory cytokines initiate and activate dendritic cells, antigen-specific helper T-cells, and B-cells, inducing pathogenic differentiation and development of plasma cells. Therefore, drugs that inhibit cytokine/chemokine activity represent an effective potential therapeutic strategy [49] . Studies have shown that abnormal proportions and functions of Breg cells can cause harmful effects in MG patients and trigger autoimmunity [50] . A better understanding of the interactions between human Breg and other immune cells, especially in the thymus of MG patients, is worth pursuing to develop new therapeutic strategies. Non-controlled studies have shown that the use of rituximab can significantly reduce or discontinue the use of steroids and other immunosuppressants [51] . Compared to acetylcholine receptor antibodies (AChR Ab+), rituximab is more effective in MuSK Ab+ MG [52] . However, side effects include infusion reactions (itching, redness, shortness of breath, and chills), infections, hematological disorders, alopecia, and atrial fibrillation [53] . In addition, drugs that inhibit cytokine/chemokine activity represent an effective potential therapeutic strategy [52] . Studies have shown that abnormal proportions and functions of Breg cells can cause harmful effects in MG patients and trigger autoimmunity [53] . A better understanding of the interactions between human Breg and other immune cells, especially in the thymus of MG patients, is worth pursuing to develop new therapeutic strategies.

The main driver of the pathology of AChR antibody-positive MG is represented by complement activation. The role of the complement cascade has been widely demonstrated in patients and MG animal models [54] . The primary function of complement is to recognize and destroy invading microorganisms through the formation of the membrane attack complex (MAC) [55] , and it also plays a crucial role in adaptive immunity by enhancing the antibody response. It is associated with clearing apoptotic cells and immune complexes [56] . Anti-C5 therapy has been used in patients with gMG and NMOSD, two neurological disorders driven by different pathogenic autoantibodies, which have become catalysts for developing complement inhibitors in this field [57] . Targeting the complement cascade represents a new strategy based on pathological mechanism principles. Therefore, compared with current conventional therapies, it has the potential for faster and better disease control with higher tolerance and safety. Zilucoplan is a C5 macrocyclic peptide inhibitor undergoing preclinical development, which can be self-administered via daily SC injection to rapidly and powerfully reduce complement activity and improve patient symptoms, demonstrating good safety and tolerability in Phase I and II studies [58] . Eculizumab, a monoclonal antibody, prevents the cleavage of C5 and inhibits complement-mediated membrane lysis [59] . It was approved by the FDA for AChR-positive MG patients in 2017 [60] , becoming the first FDA-approved complement inhibition therapy for MG. For patients with antibodies that activate the complement cascade, this drug can effectively improve symptoms but requires a combination with immunosuppressive treatment, as eculizumab only inhibits terminal complement activation [61] . Ravulizumab is the next-generation eculizumab, a monoclonal antibody targeting complement C5. It is modified by four amino acid substitutions on the heavy chain of the drug, promoting the separation of C5 within the nuclear body. Changing the Fc fragment also increases ravulizumab’s affinity for FcRn, avoiding intracellular degradation and prolonging its half-life in the blood [39] . Zilucoplan is a synthetic macrolide drug with a more extraordinary relationship for inhibiting C5 complement cleavage and also binds to preformed C5b, blocking its interaction with the C6 complement [58] . It was initially developed as a replacement for eculizumab-resistant patients with paroxysmal nocturnal hemoglobinuria (PNH), with the advantages of self-administration and rapid SC administration [17] . In summary, complement inhibitors are expected to become a new standard for treating generalized severe myasthenia gravis patients, providing earlier treatment for more patients. This will reduce dosing frequency and patient burden, increasing patient compliance with treatment.